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BMMC-AMI TRIALS 2002 TO 2015
A key challenge in regenerative medical treatment for AMI is the shifting landscape of the disease. Importantly, the case fatality rate of acute ST-segment elevation myocardial infarction has fallen dramatically by 24.2% in the last 3 decades caused in large part by aggressive reperfusion therapy (6) . Randomized trials have collectively demonstrated reduced mortality, improved event-free survival, and fewer reinfarctions with time-sensitive door-to-balloon primary PCI (7, 8) .
Nevertheless, preventing coronary artery disease progression and development of post-MI heart failure remains a major challenge. Therefore, multiple randomized and nonrandomized (9) Figure 1B) . Interestingly, trials that have enrolled patients with lower EF have shown benefit from cell therapy (11, 12) . We cannot disregard the fact that a few trials (13, 14) showed a significant infarct size reduction, whereas almost all investigators described a nonsignificant reverse cardiac remodeling in cell-treated groups.
Meta-analyses of BMMC trials for AMI demonstrated that intracoronary cell therapy significantly decreases infarct size (19) and overall improves LVEF by 2.99% (20) . The review of most G-CSF trials did not show any beneficial effects in moderate (<45%) or severe (<35%) LV dysfunction ( Table 1 
